NP Theresa Stukus and NP Nelli Zafman discuss the practical challenges patients with metastatic triple-negative breast cancer ...

The U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) on October 7, ...

In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient ...

An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology ...

Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are ...

The FDA has approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 2 years and older w ...

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton ...

September marks Gynecologic Cancer Awareness Month, an annual observation focused on increasing public and clinical awareness of gynecologic malignancies, including ovarian, endometrial, cervical, ...

NP Theresa Stukus and NP Nelli Zafman discuss long-term management considerations for a patient with metastatic ...

At ASTRO 2026, Dr. Nitin Ohri details additive versus synergistic toxicities when combining radiation with novel systemic therapies in clinical trials. At the American Society for Radiation Oncology ...

Patients with prostate cancer can receive radiation after prostatectomy in 25 treatments over 5 weeks instead of 37 treatments over 7 weeks. Long-term data from the NRG-GU003 tria ...

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles. On Sept. 28, 2026, oncology healthcare professionals convened at the ...